Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

Research output: Contribution to journal › Review › Research › peer-review

Standard

Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. / Tschöp, Matthias H; Finan, Brian; Clemmensen, Christoffer; Gelfanov, Vasily; Perez-Tilve, Diego; Müller, Timo D; DiMarchi, Richard D.

In: Cell Metabolism, Vol. 24, No. 1, 12.07.2016, p. 51-62.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Tschöp, MH, Finan, B, Clemmensen, C, Gelfanov, V, Perez-Tilve, D, Müller, TD & DiMarchi, RD 2016, 'Unimolecular Polypharmacy for Treatment of Diabetes and Obesity', Cell Metabolism, vol. 24, no. 1, pp. 51-62. https://doi.org/10.1016/j.cmet.2016.06.021

APA

Tschöp, M. H., Finan, B., Clemmensen, C., Gelfanov, V., Perez-Tilve, D., Müller, T. D., & DiMarchi, R. D. (2016). Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. Cell Metabolism, 24(1), 51-62. https://doi.org/10.1016/j.cmet.2016.06.021

Vancouver

Tschöp MH, Finan B, Clemmensen C, Gelfanov V, Perez-Tilve D, Müller TD et al. Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. Cell Metabolism. 2016 Jul 12;24(1):51-62. https://doi.org/10.1016/j.cmet.2016.06.021

Author

Tschöp, Matthias H ; Finan, Brian ; Clemmensen, Christoffer ; Gelfanov, Vasily ; Perez-Tilve, Diego ; Müller, Timo D ; DiMarchi, Richard D. / Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. In: Cell Metabolism. 2016 ; Vol. 24, No. 1. pp. 51-62.

Bibtex

@article{34d3d69e4b29459fa9d92b14f7abb81e,
title = "Unimolecular Polypharmacy for Treatment of Diabetes and Obesity",
abstract = "Many complex diseases have historically proven to be defiant to the best mono-therapeutic approaches. Several examples of combination therapies have largely overcome such challenges, notably for the treatment of severe hypertension and tuberculosis. Obesity and its consequences, such as type 2 diabetes, have proven to be equally resistant to therapeutic approaches based on single medicines. Proper management of type 2 diabetes often requires adjunctive medications, and the recent registration of a few compound mixtures has set the precedent for combinatorial treatment of obesity. On the other hand, double or triple therapeutic combinations are more difficult to advance to regulatory approval than single molecules. More recently, several classes of novel unimolecular combination therapeutics have emerged with superior efficacy than currently prescribed options and pose the potential to reverse obesity and type 2 diabetes. Here, we summarize the discovery, pre-clinical validation, and first clinical test of such peptide hormone poly-agonist drug candidates.",
keywords = "Amino Acid Sequence, Bariatric Surgery, Diabetes Mellitus, Type 2, Glucagon, Humans, Obesity, Peptides, Polypharmacy, Journal Article, Review",
author = "Tsch{\"o}p, {Matthias H} and Brian Finan and Christoffer Clemmensen and Vasily Gelfanov and Diego Perez-Tilve and M{\"u}ller, {Timo D} and DiMarchi, {Richard D}",
note = "Copyright {\textcopyright} 2016 Elsevier Inc. All rights reserved.",
year = "2016",
month = jul,
day = "12",
doi = "10.1016/j.cmet.2016.06.021",
language = "English",
volume = "24",
pages = "51--62",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "1",

}

RIS

TY - JOUR

T1 - Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

AU - Tschöp, Matthias H

AU - Finan, Brian

AU - Clemmensen, Christoffer

AU - Gelfanov, Vasily

AU - Perez-Tilve, Diego

AU - Müller, Timo D

AU - DiMarchi, Richard D

N1 - Copyright © 2016 Elsevier Inc. All rights reserved.

PY - 2016/7/12

Y1 - 2016/7/12

N2 - Many complex diseases have historically proven to be defiant to the best mono-therapeutic approaches. Several examples of combination therapies have largely overcome such challenges, notably for the treatment of severe hypertension and tuberculosis. Obesity and its consequences, such as type 2 diabetes, have proven to be equally resistant to therapeutic approaches based on single medicines. Proper management of type 2 diabetes often requires adjunctive medications, and the recent registration of a few compound mixtures has set the precedent for combinatorial treatment of obesity. On the other hand, double or triple therapeutic combinations are more difficult to advance to regulatory approval than single molecules. More recently, several classes of novel unimolecular combination therapeutics have emerged with superior efficacy than currently prescribed options and pose the potential to reverse obesity and type 2 diabetes. Here, we summarize the discovery, pre-clinical validation, and first clinical test of such peptide hormone poly-agonist drug candidates.

AB - Many complex diseases have historically proven to be defiant to the best mono-therapeutic approaches. Several examples of combination therapies have largely overcome such challenges, notably for the treatment of severe hypertension and tuberculosis. Obesity and its consequences, such as type 2 diabetes, have proven to be equally resistant to therapeutic approaches based on single medicines. Proper management of type 2 diabetes often requires adjunctive medications, and the recent registration of a few compound mixtures has set the precedent for combinatorial treatment of obesity. On the other hand, double or triple therapeutic combinations are more difficult to advance to regulatory approval than single molecules. More recently, several classes of novel unimolecular combination therapeutics have emerged with superior efficacy than currently prescribed options and pose the potential to reverse obesity and type 2 diabetes. Here, we summarize the discovery, pre-clinical validation, and first clinical test of such peptide hormone poly-agonist drug candidates.

KW - Amino Acid Sequence

KW - Bariatric Surgery

KW - Diabetes Mellitus, Type 2

KW - Glucagon

KW - Humans

KW - Obesity

KW - Peptides

KW - Polypharmacy

KW - Journal Article

KW - Review

U2 - 10.1016/j.cmet.2016.06.021

DO - 10.1016/j.cmet.2016.06.021

M3 - Review

C2 - 27411008

VL - 24

SP - 51

EP - 62

JO - Cell Metabolism

JF - Cell Metabolism

SN - 1550-4131

IS - 1

ER -

ID: 186640087